
Dulaglutide (Trulicity)
Dulaglutide (Trulicity) is a once-weekly injectable GLP-1 drug for type 2 diabetes. In the REWIND trial of 9,901 adults followed for a median of 5.4 years, it lowered major cardiovascular events by about 12% compared with placebo, and higher doses lower HbA1c and weight a little more than 1.5 mg. It also improved blood sugar in children 10 and older. Nausea, diarrhea and vomiting are common, and the label carries a boxed warning about thyroid C-cell tumors seen in rats.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults and children 10 years and older with type 2 diabetes, and adults with type 2 diabetes plus established cardiovascular disease or multiple cardiovascular risk factors, whose prescriber recommends a weekly injection
Common dosing range
Set by your prescriber. Adults start at 0.75 mg once weekly; the dose may rise to 1.5 mg, then in 1.5 mg steps at least 4 weeks apart up to 4.5 mg once weekly. Children 10 and older: 0.75 mg weekly, up to 1.5 mg
When to expect effects
Steady blood levels within 2 to 4 weeks; HbA1c changes were measured at 26 to 36 weeks in trials
Watch out for
Boxed warning: thyroid C-cell tumors in rats; it must not be used with a personal or family history of medullary thyroid cancer or MEN 2. Stomach side effects are common. Other risks include pancreatitis, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, gallbladder disease and diabetic eye complications
What is it
Dulaglutide is a prescription GLP-1 receptor agonist injected under the skin once a week, sold as Trulicity single-dose pens by Eli Lilly. The Trulicity label approves it, alongside diet and exercise, to improve blood sugar control in adults and children 10 years and older with type 2 diabetes, and to lower the risk of major cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Its label covers type 2 diabetes only: it is not approved for type 1 diabetes or as a weight-loss medicine.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
lowering major cardiovascular events in type 2 diabetes Good Evidence | Modest; about 12% fewer major cardiovascular events | Adults 50 and older with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors | Measured over a median of 5.4 years |
blood sugar control in adults with type 2 diabetes (higher doses) Good Evidence | All doses lowered HbA1c by about 1.5 to 1.8 points; 4.5 mg added about 0.24 points over 1.5 mg | Adults with type 2 diabetes on metformin who need more blood sugar lowering | Measured at 36 weeks |
blood sugar control in children and teens with type 2 diabetes Good Evidence | About 1.2 to 1.5 points lower HbA1c than placebo | Children and teens 10 years and older with type 2 diabetes | Measured at 26 weeks |
body mass index in children and teens with type 2 diabetes Limited Evidence | No difference from placebo | Children and teens 10 years and older with type 2 diabetes | Measured at 26 weeks |
lowering major cardiovascular events in type 2 diabetes
- Effect
- Modest; about 12% fewer major cardiovascular events
- Best fit
- Adults 50 and older with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
- Time
- Measured over a median of 5.4 years
blood sugar control in adults with type 2 diabetes (higher doses)
- Effect
- All doses lowered HbA1c by about 1.5 to 1.8 points; 4.5 mg added about 0.24 points over 1.5 mg
- Best fit
- Adults with type 2 diabetes on metformin who need more blood sugar lowering
- Time
- Measured at 36 weeks
blood sugar control in children and teens with type 2 diabetes
- Effect
- About 1.2 to 1.5 points lower HbA1c than placebo
- Best fit
- Children and teens 10 years and older with type 2 diabetes
- Time
- Measured at 26 weeks
body mass index in children and teens with type 2 diabetes
- Effect
- No difference from placebo
- Best fit
- Children and teens 10 years and older with type 2 diabetes
- Time
- Measured at 26 weeks
Evidence for 4 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
lowering major cardiovascular events in type 2 diabetes
Disease adjunctIn the double-blind REWIND trial, 9,901 adults aged 50 or older with type 2 diabetes and either previous cardiovascular disease or cardiovascular risk factors (mean age 66, median HbA1c 7.2%) took dulaglutide 1.5 mg weekly or placebo. Over a median of 5.4 years, nonfatal heart attack, nonfatal stroke or cardiovascular death occurred in 12.0% on dulaglutide versus 13.4% on placebo (hazard ratio 0.88). Death from any cause did not differ significantly (10.8% vs 12.0%). Stomach and bowel side effects were reported by 47.4% versus 34.1%. The trial was funded by the manufacturer.
Bottom line: Weekly dulaglutide modestly lowered heart attacks, strokes and cardiovascular deaths in people with type 2 diabetes over about 5 years.
blood sugar control in adults with type 2 diabetes (higher doses)
Biomarker supportIn the AWARD-11 trial, 1,842 adults with type 2 diabetes not controlled on metformin (mean HbA1c 8.6%, mean BMI 34.2) took dulaglutide 1.5, 3.0 or 4.5 mg weekly for 52 weeks. At 36 weeks, HbA1c fell by 1.77 points on 4.5 mg versus 1.54 on 1.5 mg, and weight fell by 4.6 kg versus 3.0 kg. The 3.0 mg dose beat 1.5 mg on HbA1c only in one of the two planned analyses. Nausea occurred in 13.4%, 15.6% and 16.4%, and vomiting in 5.6%, 8.3% and 9.3%, on the three doses. There was no placebo group, so the trial compares the doses with each other, not with no treatment.
Bottom line: Dulaglutide lowered HbA1c by about 1.5 to 1.8 points, and stepping up to 4.5 mg gave a little more lowering and weight loss than 1.5 mg.
blood sugar control in children and teens with type 2 diabetes
Biomarker supportIn the double-blind AWARD-PEDS trial, 154 young people aged 10 to under 18 with type 2 diabetes and a BMI above the 85th percentile, treated with lifestyle changes alone or with metformin with or without basal insulin, took dulaglutide 0.75 mg, 1.5 mg or placebo weekly. At 26 weeks, HbA1c rose 0.6 points on placebo and fell 0.6 and 0.9 points on the two doses, and 51% on dulaglutide versus 14% on placebo reached an HbA1c below 7.0%. BMI did not change differently between groups. Stomach side effects were more common with dulaglutide.
Bottom line: In children and teens with type 2 diabetes, weekly dulaglutide lowered HbA1c, while it rose on placebo.
body mass index in children and teens with type 2 diabetes
No benefit foundIn the same 26-week AWARD-PEDS trial of 154 young people with type 2 diabetes, BMI was a secondary outcome, and there were no differences between the dulaglutide and placebo groups in the change in BMI.
Bottom line: In children with type 2 diabetes, dulaglutide did not change BMI more than placebo over 26 weeks.
How it works
How to take it
What to track
Bottom line: One injection a week, on a schedule your prescriber sets; watch blood sugar if you also use insulin or a sulfonylurea.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Risk of thyroid C-cell tumors (boxed warning). Dulaglutide caused dose-related thyroid C-cell tumors in rats after lifetime exposure. It is unknown whether it causes them, including medullary thyroid cancer, in humans. It is contraindicated with a personal or family history of medullary thyroid cancer or with MEN 2. One case of medullary thyroid cancer occurred in a trial patient whose calcitonin was already about 8 times the upper limit of normal before treatment.
Acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been seen with GLP-1 drugs including Trulicity. The label says to stop it if pancreatitis is suspected.
Low blood sugar with insulin or sulfonylureas; severe stomach and bowel reactions; acute kidney injury after dehydration from vomiting or diarrhea; serious allergic reactions including anaphylaxis and angioedema.
Diabetic eye complications (in REWIND, 8.5% versus 6.2% on placebo among people who already had diabetic retinopathy), gallbladder disease such as gallstones and cholecystitis, and food remaining in the stomach during anesthesia or deep sedation, which can lead to pulmonary aspiration.
Who should avoid it
- People with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2 (contraindicated)
- People with a previous serious allergic reaction to dulaglutide or any product component (contraindicated), and caution after anaphylaxis or angioedema with another GLP-1 drug
- People with severe gastroparesis (not recommended)
- Children under 10 years, in whom safety and effectiveness have not been established; caution is advised in end-stage kidney disease and liver impairment
Pregnancy & breastfeeding
Pregnancy: the Trulicity label says the limited data in pregnant women are not enough to determine a drug-related risk of birth defects or miscarriage, that animal studies suggest possible risk to the fetus, and that it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It also notes that poorly controlled diabetes in pregnancy carries its own risks to mother and baby, so pregnancy plans belong in a talk with your doctor. Breastfeeding: there are no data on dulaglutide in human milk, on the breastfed infant or on milk production; the label says to weigh the benefits of breastfeeding against the mother's need for Trulicity and any possible effects on the child.
Interactions
Together they raise the risk of low blood sugar, including severe episodes. The label says a lower dose of the insulin or sulfonylurea may be considered when Trulicity is started. Your prescriber decides, and you should know the signs of low blood sugar.
Dulaglutide slows stomach emptying and can slow the absorption of tablets taken by mouth, most after the first dose. At 1.5 mg it did not change absorption of tested medicines to a clinically relevant degree, but experience at 3 mg and 4.5 mg is limited. The label says levels of narrow-range medicines such as warfarin should be monitored.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is Trulicity approved for weight loss?⌄
No. The Trulicity label approves it to improve blood sugar control in type 2 diabetes (adults and children 10 and older) and to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. People often lose some weight on it, for example 3.0 to 4.6 kg at 36 weeks in one trial, but weight loss is not an approved use.
Can I take my supplements with dulaglutide?⌄
Our interaction database has no supplement pairs for dulaglutide, and we found no studies testing supplements with it. Because it lowers blood sugar and slows stomach emptying, ask your doctor or pharmacist to review any supplement marketed for blood sugar and any medicine taken by mouth that needs exact levels.
What if I miss a weekly dose?⌄
The label says to inject the missed dose as soon as possible if at least 3 days (72 hours) remain until your next scheduled dose. If less than 3 days remain, skip it and take the next dose on your usual day. Do not change your plan without asking your prescriber.
Does dulaglutide protect the heart?⌄
In the REWIND trial of 9,901 adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, dulaglutide 1.5 mg lowered heart attacks, strokes and cardiovascular deaths combined by about 12% over a median of 5.4 years compared with placebo. Death from any cause did not differ significantly. It was not tested in people without diabetes.
Can it be used with insulin?⌄
Yes, the label allows it, but the risk of low blood sugar goes up and your prescriber may lower the insulin dose. Inject them separately and never mix them in one syringe; the same body area is fine as long as the injections are not right next to each other.
References by claim
lowering major cardiovascular events in type 2 diabetes
Gerstein et al., 2019 · PubMed (2019) link
blood sugar control in adults with type 2 diabetes (higher doses)
Frias et al., 2021 · PMC (2021) link
blood sugar control in children and teens with type 2 diabetes
Arslanian et al., 2022 · PubMed (2022) link
Safety
Trulicity (dulaglutide) prescribing information · DailyMed (FDA label) link
Track Dulaglutide (Trulicity) with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
